サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1493358

米国の自己免疫疾患診断の市場規模、シェア、動向分析レポート：タイプ別、検査タイプ別、最終用途別、セグメント別予測、2024-2030年

U.S. Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Test Type, By End-use, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 125 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
米国の自己免疫疾患診断の市場規模、シェア、動向分析レポート：タイプ別、検査タイプ別、最終用途別、セグメント別予測、2024-2030年
出版日: 2024年05月28日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の自己免疫疾患診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の自己免疫疾患診断市場規模は2030年までに30億1,000万米ドルに達し、2024年から2030年までのCAGRは5.2％で成長すると予測されています。

自己免疫疾患の罹患率の上昇と、診断ツールや診断技術における技術進歩の増加が、市場の成長を大きく促進しています。

医療従事者や患者の自己免疫疾患に対する意識の高まりが、診断やスクリーニングの実施率の上昇につながっています。公衆衛生への取り組み、教育キャンペーン、アドボカシー活動により、自己免疫疾患の徴候や症状に対する認識が高まり、早期診断や治療を求める人が増えています。高リスク集団を対象としたスクリーニング・プログラムも、自己免疫疾患の早期発見に寄与しています。

世界のヘルスケア支出の増加と、自己免疫疾患によるヘルスケアシステムへの負担の増大が、高度な診断ソリューションの需要に拍車をかけています。政府や民間団体は、自己免疫疾患がもたらす課題に対処するため、ヘルスケアインフラや研究開発に投資しています。この投資は診断技術の革新を促進し、自己免疫疾患患者の質の高い診断サービスへのアクセスを促進します。

米国の自己免疫疾患診断市場レポート・ハイライト

  • 罹患組織や臓器の詳細な可視化を可能にする超音波、MRI、PETスキャンなどの高度な画像診断技術の台頭により、局所自己免疫疾患診断タイプが2023年に66.0%のシェアで市場を独占しました。
  • 抗核抗体検査タイプが2023年に最大の市場シェアを占め、予測期間中に最も速い成長が見込まれます。
  • 正確で精密な検査法へのニーズの高まりから、病院の最終用途分野が2023年の市場を独占しました。
  • 2023年11月、Progentec DiagnosticsとMayo Clinic Laboratoriesは、自己免疫疾患の早期発見と治療のためのProgentecの特許取得済みバイオマーカー血液検査製品群を商業化するための戦略的提携を発表しました。この提携は、米国およびいくつかの国際市場における患者および臨床医のアクセシビリティの向上を目指すものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の自己免疫疾患診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 米国の自己免疫疾患診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の自己免疫疾患診断市場：タイプ推定・動向分析

  • タイプ別市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 米国の自己免疫疾患診断市場タイプ別展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 自己免疫疾患診断
  • 限局性自己免疫疾患診断

第5章 米国の自己免疫疾患診断市場：検査タイプの推定・動向分析

  • 検査タイプの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 米国の自己免疫疾患診断市場の検査タイプ別展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 抗核抗体検査
  • 自己抗体検査
  • C反応性蛋白
  • 全血球計算
  • 尿検査
  • その他

第6章 米国の自己免疫疾患診断市場：最終用途の推定・動向分析

  • 最終用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 最終用途別見通しによる米国の自己免疫疾患診断市場
  • 2018年から2030年までの市場規模と予測および動向分析
  • 病院
  • 診断センター
  • その他

第7章 米国の自己免疫疾患診断市場：地域推定・動向分析

  • 地域別市場シェア、2023年および2030年
  • 米国の自己免疫疾患診断市場の地域別展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 西部
  • 中西部
  • 北東部
  • 南西部
  • 南東部

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 企業プロファイル
    • Medtronic
    • Boston Scientific Corporation
    • Johnson &Johnson Service Inc.（Ethicon, Inc.）
    • AngioDynamics
    • Bioventus Inc.（Misonix Inc.）
    • EDAP TMS
    • Chongqing Haifu Medical Technology Co., Ltd
    • Mermaid Medical
    • HealthTronics, Inc.
    • HS Hospital Service SpA
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. autoimmune disease diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 U.S. systemic autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. localized autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. autoimmune disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. autoimmune disease diagnostics market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. Autoimmune disease diagnostics market: market outlook
  • Fig. 9 U.S. Autoimmune disease diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. Autoimmune disease diagnostics market driver impact
  • Fig. 14 U.S. Autoimmune disease diagnostics market restraint impact
  • Fig. 15 U.S. Autoimmune disease diagnostics market: Type movement analysis
  • Fig. 16 U.S. Autoimmune disease diagnostics market: Type outlook and key takeaways
  • Fig. 17 Systemic autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Ankylosing spondylitis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Systemic lupus erythematosus (SLE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Localized autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Multiple sclerosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Type 1 diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hashimoto's Thyroiditis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Idiopathic thrombocytopenic purpura market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Autoimmune disease diagnostics Market: Treatment movement Analysis
  • Fig. 29 U.S. Autoimmune disease diagnostics market: Treatment outlook and key takeaways
  • Fig. 30 Surgical ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Percutaneous ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Laparoscopic ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Autoimmune disease diagnostics market: application movement analysis
  • Fig. 34 U.S. Autoimmune disease diagnostics market: application outlook and key takeaways
  • Fig. 35 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Autoimmune disease diagnostics market: regional movement analysis
  • Fig. 42 U.S. Autoimmune disease diagnostics market: regional outlook and key takeaways
  • Fig. 43 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-285-3

U.S. Autoimmune Disease Diagnostics Market Growth & Trends:

The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques are significantly driving the growth of the market.

Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.

The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.

U.S. Autoimmune Disease Diagnostics Market Report Highlights:

  • Localized autoimmune disease diagnostics type dominated the market with a 66.0% share in 2023 owing to the rising advanced imaging techniques, such as ultrasound, MRI, and PET scans, which allow for detailed visualization of affected tissues or organs.
  • The antinuclear antibody test type segment held the largest market share in 2023 and is anticipated to witness the fastest growth over the forecast period.
  • The hospitals end-use segment dominated the market in 2023 owing to the growing need for accurate and precise testing methods.
  • In November 2023, Progentec Diagnostics and Mayo Clinic Laboratories announced a strategic partnership to commercialize Progentec's range of patented biomarker blood tests for the early detection and treatment of autoimmune disorders. The partnership seeks to improve accessibility for patients and clinicians in the United States and a few international markets.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Test type outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Autoimmune Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Presence of research funding programs
      • 3.2.1.2. Presence of favorable government initiatives
      • 3.2.1.3. Growing patient awareness levels
      • 3.2.1.4. Technological innovation in the form of lab automation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled
  • 3.3. U.S. Autoimmune Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Autoimmune Disease Diagnostics Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. U.S. Autoimmune Disease Diagnostics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Rheumatoid arthritis
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ankylosing spondylitis diagnostics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Systemic lupus erythematosus (SLE)
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Localized autoimmune disease diagnostics
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Multiple sclerosis
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Type 1 diabetes
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Hashimoto's Thyroiditis
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Idiopathic thrombocytopenic purpura
      • 4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
      • 4.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Autoimmune Disease Diagnostics Market by Test Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Antinuclear antibody tests
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Autoantibody tests
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. C-reactive Protein (CRP)
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Complete blood count (CBC)
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Urinalysis
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Autoimmune Disease Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Autoimmune Disease Diagnostics Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic centers
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Autoimmune Disease Diagnostics Market: Region Estimates & Trend Analysis

  • 7.1. Regional Market Share, 2023 & 2030
  • 7.2. U.S. Autoimmune Disease Diagnostics Market by Region Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.3.1. West
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Midwest
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Northeast
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Southwest
      • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.5. Southeast
      • 7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Medtronic
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. AngioDynamics
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bioventus Inc. (Misonix Inc.)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. EDAP TMS
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Chongqing Haifu Medical Technology Co., Ltd
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Mermaid Medical
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HealthTronics, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. H.S. Hospital Service S.p.A.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives